This echoes the neuropathology literature demonstrating that individuals with greater pathological burden (i.e., greater subcortical tau deposition) exhibit diminished volumes of nuclei known to contain the first signs of AD-related pathology and perform worse on corresponding cognitive tests (Braak and Del Tredici 2015; Grudzien et al. 2007). The gene discussed is MAPT; the disease is Alzheimer disease.